Geographical variations in TP53 mutational spectrum in ovarian carcinomas

Annals of Human Genetics

Volumn 70, Issue 5, 2006, Pages 594-604

  Dansonka Mieszkowska, A ^a   Ludwig, A H ^a   Kraszewska, E ^a   Kupryjanczyk J ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER STAGING; CODON; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GENOME ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; KOREA; MAJOR CLINICAL STUDY; MUTATION RATE; NORWAY; OVARY CARCINOMA; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; UNITED KINGDOM;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AMINO ACID SUBSTITUTION; CARCINOMA, ENDOMETRIOID; CODON; CYSTADENOCARCINOMA, SEROUS; EXONS; FEMALE; GENES, P53; GEOGRAPHY; HUMANS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; VARIATION (GENETICS);

EID: 33746822703     PISSN: 00034800     EISSN: 14691809     Source Type: Journal    
DOI: 10.1111/j.1469-1809.2006.00257.x     Document Type: Article

References (68)

1. Arlt, V. M. et al. (2001) Sequence-specific detection of aristolochic acid-DANN adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22, 133-140.
2. Boyle, P. & Leake, P. E. (1996) Epidemiological and biological interactions. In: Ovarian cancer 4 (eds, F. Sharp, T. Blackett, R. Leake & J. Berek) pp. 91-101. London, Glasgow: Chapman & Hall medical.
3. Buller, R. E. et al. (2001) The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res. 7, 831-838.
4. Casey, G. et al. (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13, 1971-1981.
5. Chan, K. T. et al. (2003) In vitro aflatoxin B1-induced p53 mutations. Cancer Lett 199, 1-7.
6. Chen, J. X. et al. (1998) Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res 58, 2070-2075.
7. Creasman, W. J. (1989) Announcement, FIGO stages 1988, Revisions. Gynecol Oncol 35, 125-127.
8. Denissenko, M. F. et al. (1997) Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc Natl Acad Sci USA 94, 3893-3838.
9. DiCioccio, R. A. et al. (1998) Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet 105, 93-102.
10. Fallows, S. et al. (2001) P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 194, 68-75.
11. Foulkes, W. D. et al. (1995) MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 72, 883-888.
12. Fujita, M. et al. (1994) Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 85, 1247-1256.
13. Greenblatt, M. S. et al. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 4855-4878.
14. Hartmann, A. et al. (1997) The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13, 27-33.
15. Hollstein, M. et al. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22, 3551-3555.
16. Hollstein, M. et al. (1998) On the origins of tumor mutations in cancer genes: Insights from the p53 gene. Mutation Res 405, 145-154.
17. Hussain, S. P. & Harris, C. C. (2000) Molecular epidemiology and carcinogenesis: Endogenous and exogenous carcinogens. Mutat Res 462, 311-322.
18. Inoue, M., et al. (1994) Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 102, 665-70.
19. Jacobs, I. J. et al. (1992) Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84, 1793-1798.
20. Kappes, S. et al. (1995) P53 mutations in ovarian tumors, detected by temperature- gradient gel eletrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 64, 52-59.
21. Kihana, T. et al. (1992) High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 83, 978-984.
22. Kim, J. W. et al. (1995) Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol 57, 199-204.
23. Kohler, M. F. et al. (1993a) Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81, 643-650.
24. Kohler, M. F. et al. (1993b) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85, 1513-1519.
25. Kupryjanczyk, J. et al. (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90, 4961-4965.
26. Kupryjanczyk, J. et al. (1995) p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 26, 387-392.
27. Kupryjanczyk, J. et al. (2000) Spontaneous apoptosis in ovarian carcinomas: A positive association with p53 gene mutation is dependent on growth fraction. Br J Cancer 82, 579-83.
28. Kupryjanczyk, J. et al. (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88, 848-854.
29. Lasky, T. & Silbergeld, E. (1996) P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. Environ Health Perspect 104, 1324-1331.
30. Lavarino, C. et al. (2000) p53 gene status and response to platinum/ paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18, 3936-3945.
31. Lee, J. H. et al. (1995) p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 85, 43-50.
32. Leitao, M. M. et al. (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol. 93, 301-306.
33. Lutz, W. K. et al. (1998) Position- and base pair-specific comparison of p53 mutation spectra in human tumors: Elucidation of relationships between organs for cancer etiology. Environ Health Perspect 106, 207-211.
34. Mazars, R. et al. (1991) p53 mutations in ovarian cancer: A late event ?Oncogene 6, 1685-1690.
35. Meinhold-Heerlein, I. et al. (2001) Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology. 60, 176-188.
36. Milner, B. J. et al. (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53, 2128-32.
37. Mok, C. H. et al. (1992) Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52, 5119-5122.
38. Nagao, M. (1999) A new approach to risk estimation of food-borne carcinogens-heterocyclic amines-based on molecular information. Mutat Res 431, 3-12.
39. Naito, M. et al. (1992) Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 83, 1030-1036.
40. Niwa, K. et al. (1994) Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70, 1191-1197.
41. Olivier, M. & Hainaut, P. (2001) TP53 mutation patterns in breast cancers: Searching for clues of environmental carcinogenesis. Cancer Biol 11, 353-360.
42. Olivier, M. et al. (2002) The IARC TP53 Database: New online mutation analysis and recommendations to users. Hum Mutat 19, 607-614.
43. Otsuka, J. et al. (2004) Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 14, 459-464.
44. Peterson, F. et al. (1988) Annual report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics.
45. Rhei, E. et al. (1998) Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 58, 3193-3196.
46. Righetti, S. C. et al. (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56, 689-693.
47. Robles, A. I. et al. (2002) The p53 network in lung carcinogenesis. Oncogene 21, 6898-6907.
48. Russell, P. (1994) Surface epithelial-stromal tumors of the ovary. In: Blaustein ' s pathology of the female genital tract. (ed Kurman R. J.), pp 705-782. New York Berlin Heidelberg: Springer Verlag.
49. Sakamoto, T. et al. (1996) Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers. Gynecol Oncol 63, 173-179.
50. Sarhanis, P. et al. (1996) Epithelial ovarian cancer: Influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression. Br J Cancer 74, 1757-1761.
51. Sato, S. et al. (1999) Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 86, 1307-1313.
52. Shigemasa, K. et al. (1999) Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Invest 6, 102-108.
53. Sigal, A. & Rotter, V. (2000) Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 60, 6788-6793.
54. Skilling, J. S. et al. (1996) An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13, 117-123.
55. Skomedal, H. et al. (1997) TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181, 158-165.
56. Smith-Sorensen, B. et al. (1998) Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78, 375-381.
57. Soussi, T. & Béroud, C. (2003) Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. Human Mut 21, 192-200.
58. Tang, R. et al. (2001) Mutations of p53 gene in human colorectal cancer: distinct frameshifts among populations. Int J Cancer 91, 863-868.
59. Tavassoli, M. et al. (1996) Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. Br J Cancer 74, 115-119.
60. Teneriello, M. G. et al. (1993) p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53, 3103-3108.
61. Tworek, H. et al. (1999) Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet 112, 105-118.
62. Vautier, G. et al. (1999) p53 mutations in british patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 117, 154-160.
63. Wang, Y. et al. (2004) TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer. 90, 678-685.
64. Wang, Y. et al. (2004) Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat. 24, 21-34.
65. Watanabe, M. et al. (1997) Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 18, 1355-1358.
66. Wen, W. H. et al. (1999) p53 mutations and expression in ovarian cancers: Correlation with overall survival. Int J Gynecol Pathol 18, 29-41.
67. Wertheim, I. et al. (1994) p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86, 1549-1551.
68. Zheng, J. et al. (1995) Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 87, 1146-1153.